SWITCH BETWEEN REFERENCE ETANERCEPT (ETN) AND GP2015, AN ETANERCEPT BIOSIMILAR, DID NOT IMPACT EFFICACY AND SAFETY IN PATIENTS WITH MODERATE-TO-SEVERE RHEUMATOID ARTHRITIS: 48-WEEK RESULTS FROM THE PHASE 3 EQUIRA STUDY

被引：5
|
作者：
Matucci-Cerinic, M. [1 ]
Schulze-Koops, H. [2 ]
Buch, M. [3 ]
Kavanaugh, A. [4 ]
Allanore, Y. [5 ]
Kucharz, E. J. [6 ]
Babic, G. [7 ]
机构：
[1] Univ Florence, Florence, Italy
[2] Ludwig Maximillans Univ, Munich, Germany
[3] Univ Leeds, Leeds, W Yorkshire, England
[4] Univ Calif San Diego, Sch Med, La Jolla, CA 92093 USA
[5] Paris Descartes Univ, Cochin Hosp, Paris, France
[6] Med Univ Silesia, Katowice, Poland
[7] Hexal AG, Holzkirchen, Germany
来源：
ANNALS OF THE RHEUMATIC DISEASES | 2018年 / 77卷
关键词：
D O I：
10.1136/annrheumdis-2018-eular.1368
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
FRI0129
引用
收藏
页码：609 / 609
页数：1
相关论文
共 50 条
  • [31] Efficacy and safety of ixekizumab in Chinese patients with moderate-to-severe plaque psoriasis: 12-week results from a phase 3 study
    Rui, Wenlong
    Li, Xia
    Zheng, Jie
    Pan, Weili
    Zheng, Min
    Lu, Yan
    Li, Fuqiu
    Ding, Yangfeng
    Zhang, Jianzhong
    Li, Hongying
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2021, 85 (03) : AB55 - AB55
  • [32] Efficacy and safety results from a randomized double-blind study comparing proposed biosimilar ABP 798 with rituximab reference product in subjects with moderate-to-severe rheumatoid arthritis
    Gerd, Burmester
    Edit, Drescher
    Pawel, Hrycaj
    David, Chien
    Pan Zhiying
    Stanley, Cohen
    CLINICAL RHEUMATOLOGY, 2020, 39 (11) : 3341 - 3352
  • [33] Efficacy and safety results from a randomized double-blind study comparing proposed biosimilar ABP 798 with rituximab reference product in subjects with moderate-to-severe rheumatoid arthritis
    Gerd Burmester
    Edit Drescher
    Pawel Hrycaj
    David Chien
    Zhiying Pan
    Stanley Cohen
    Clinical Rheumatology, 2020, 39 : 3341 - 3352
  • [34] SIMILAR EFFICACY AND SAFETY OF BIOSIMILAR CANDIDATE BI 695501 AND ADALIMUMAB ORIGINATOR REFERENCE PRODUCT IN PATIENTS WITH MODERATE TO SEVERE ACTIVE RHEUMATOID ARTHRITIS: 24 WEEK RESULTS FROM A PHASE III CLINICAL STUDY (VOLTAIRE®-RA)
    Cohen, S.
    Alonso-Ruiz, A.
    Klimiuk, P. A.
    Lee, E.
    Peter, N.
    Sonderegger, I.
    Assudani, D.
    ANNALS OF THE RHEUMATIC DISEASES, 2017, 76 : 553 - 553
  • [35] Efficacy and safety of HLX01 in patients with moderate-to-severe rheumatoid arthritis despite methotrexate therapy: a phase 3 study
    Xiaofeng Zeng
    Ju Liu
    Xiumei Liu
    Lijun Wu
    Yi Liu
    Xiangping Liao
    Huaxiang Liu
    Jiankang Hu
    Xin Lu
    Linjie Chen
    Jian Xu
    Zhenyu Jiang
    Fu-ai Lu
    Huaxiang Wu
    Ying Li
    Qingyu Wang
    Jun Zhu
    Arthritis Research & Therapy, 24
  • [36] Efficacy and safety of HLX01 in patients with moderate-to-severe rheumatoid arthritis despite methotrexate therapy: a phase 3 study
    Zeng, Xiaofeng
    Liu, Ju
    Liu, Xiumei
    Wu, Lijun
    Liu, Yi
    Liao, Xiangping
    Liu, Huaxiang
    Hu, Jiankang
    Lu, Xin
    Chen, Linjie
    Xu, Jian
    Jiang, Zhenyu
    Lu, Fu-Ai
    Wu, Huaxiang
    Li, Ying
    Wang, Qingyu
    Zhu, Jun
    ARTHRITIS RESEARCH & THERAPY, 2022, 24 (01)
  • [37] LONG-TERM SAFETY AND EFFICACY OF SB4 (ETANERCEPT BIOSIMILAR) IN PATIENTS WITH RHEUMATOID ARTHRITIS: COMPARISON BETWEEN CONTINUING SB4 AND SWITCHING FROM ETANERCEPT REFERENCE PRODUCT TO SB4
    Emery, P.
    Vencovsky, J.
    Sylwestrzak, A.
    Leszczynski, P.
    Porawska, W.
    Stasiuk, B.
    Hilt, J.
    Mosterova, Z.
    Cheong, S. Y.
    Ghil, J.
    ANNALS OF THE RHEUMATIC DISEASES, 2016, 75 : 236 - 236
  • [38] Safety and Effectiveness of Baricitinib in Chinese Patients with Moderate-to-Severe Rheumatoid Arthritis: 24-Week Results from a Post-Marketing Safety Study
    Wu, Chan-Yuan
    Wang, Qian
    Shi, Jian
    Zhang, Xiu-Ying
    Du, Rong
    Gu, Jie-Ruo
    Liu, Qi-Huan
    Yu, Jiao
    Xu, Jia-Wei
    Zhang, Yan-Jie
    Zhu, Hao
    Li, Meng-Tao
    Zeng, Xiao-Feng
    RHEUMATOLOGY AND THERAPY, 2023, 10 (06) : 1609 - 1622
  • [39] Safety and Effectiveness of Baricitinib in Chinese Patients with Moderate-to-Severe Rheumatoid Arthritis: 24-Week Results from a Post-Marketing Safety Study
    Chan-yuan Wu
    Qian Wang
    Jian Shi
    Xiu-ying Zhang
    Rong Du
    Jie-ruo Gu
    Qi-huan Liu
    Jiao Yu
    Jia-wei Xu
    Yan-jie Zhang
    Hao Zhu
    Meng-tao Li
    Xiao-feng Zeng
    Rheumatology and Therapy, 2023, 10 : 1609 - 1622
  • [40] Correction to: Efficacy and safety results from a randomized double-blind study comparing proposed biosimilar ABP 798 with rituximab reference product in subjects with moderate-to-severe rheumatoid arthritis
    Gerd Burmester
    Edit Drescher
    Pawel Hrycaj
    David Chien
    Zhiying Pan
    Stanley Cohen
    Clinical Rheumatology, 2020, 39 : 3527 - 3527
12345